Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Psoriasis Area and Severity Index

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44300   clinical trials with a EudraCT protocol, of which   7354   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: Psoriasis Area and Severity Index. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-003086-34 Sponsor Protocol Number: CAIN457A3301 Start Date*: 2013-12-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Ind...
    Medical condition: Moderate to severe chronic palmoplantar pustular psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037575 Pustular psoriasis PT
    16.1 10040785 - Skin and subcutaneous tissue disorders 10037158 Psoriasis palm & soles LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) AT (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000571-13 Sponsor Protocol Number: VIC-PSO1 Start Date*: 2011-05-24
    Sponsor Name:Gentofte Hospital
    Full Title: The effect of GLP-1 in psoriasis
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005339-15 Sponsor Protocol Number: CAIN457A3302 Start Date*: 2015-05-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 ...
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) IE (Completed) NL (Completed) CZ (Completed) SK (Completed) AT (Completed) BE (Completed) HU (Completed) SE (Completed) DE (Completed) BG (Completed) DK (Completed) FI (Completed) LV (Completed) LT (Completed) FR (Completed) GR (Completed) GB (Completed) PL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002481-31 Sponsor Protocol Number: IM011-011 Start Date*: 2017-02-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis
    Medical condition: Moderate to Severe Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2009-014364-18 Sponsor Protocol Number: 579/09 Start Date*: 2009-10-01
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PSORIASIS AND CARDIOVASCULAR DISEASE: IMMUNOMODULATOR ROLE OF THE TREATMENT WITH ROSUVASTATIN IN PATIENTS WITH PSORIASIS OF MILD OR OF MODERATE-SEVERE SKIN DISEASE.
    Medical condition: PSORIASIS
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-007011-24 Sponsor Protocol Number: 1583 Start Date*: 2007-09-21
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Assessment of endothelial function in patients with psoriasis before and after Etanercept treatment
    Medical condition: moderate to severe psoriasis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10037153 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001891-31 Sponsor Protocol Number: PS0010 Start Date*: 2016-10-27
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinectics, and Pharmacodynamics of Bimekizumab in Adult sub...
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001568-12 Sponsor Protocol Number: 16-02/CalciBet-S Start Date*: 2016-10-18
    Sponsor Name:Dermapharm AG
    Full Title: A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared ...
    Medical condition: chronic stable plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-002368-15 Sponsor Protocol Number: PS0016 Start Date*: 2016-11-15
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderat...
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003287-37 Sponsor Protocol Number: EMR200588-002 Start Date*: 2016-03-15
    Sponsor Name:Merck KGaA
    Full Title: A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-Approved Humira® in subjects with moderate to severe chro...
    Medical condition: moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000711-76 Sponsor Protocol Number: N/A Start Date*: 2020-07-13
    Sponsor Name:Alexander Egeberg
    Full Title: Efficacy of roflumilast in the treatment of psoriasis – a randomised controlled trial
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002633-34 Sponsor Protocol Number: ESK-001-006 Start Date*: 2023-02-07
    Sponsor Name:Alumis Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002532-24 Sponsor Protocol Number: 0155/2018 Start Date*: 2018-12-27
    Sponsor Name:HELM AG
    Full Title: A phase III, multicentre, randomised, double-blind, parallel-group trial to evaluate the efficacy and safety of a generic gel (calcipotriol + betamethasone 50 μg/g + 0.5 mg/g gel) compared to origi...
    Medical condition: mild to moderate plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000892-28 Sponsor Protocol Number: I1F-MC-RHBS Start Date*: 2015-08-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I1F-MC-RHBS A 52-Week Multicenter, Randomized, Blinded, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate to Severe Plaque Psor...
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) HU (Completed) NL (Completed) ES (Completed) AT (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002446-36 Sponsor Protocol Number: BP40635 Start Date*: 2018-11-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN LABEL PHASE 2A TRIAL ASSESSING THE CLINICAL EFFICACY AND SAFETY OF RO5459072 IN MODERATE TO SEVERE PSORIASIS
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005413-40 Sponsor Protocol Number: CAIN457A2313 Start Date*: 2013-04-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and longterm effi...
    Medical condition: Moderate to severe nail psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10028703 Nail psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002141-39 Sponsor Protocol Number: CDP870-040 Start Date*: 2005-10-25
    Sponsor Name:UCB Pharma S.A.
    Full Title: Multicenter, dose response, randomized, double blin, parallel, 3 arms, placebo controlled clinical trial to evaluate the efficacy and the safety of subcutaneous CDP870 (certolizumab pegol) at 2 dif...
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001066-17 Sponsor Protocol Number: CNTO1959PSO2001 Start Date*: 2012-04-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X...
    Medical condition: Moderate to Severe Plaque-type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004230-42 Sponsor Protocol Number: 18562 Start Date*: 2020-07-31
    Sponsor Name:Radboudumc
    Full Title: Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio study
    Medical condition: psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037155 Psoriasis and similar disorders LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002970-22 Sponsor Protocol Number: I1F-MC-RHAZ(c) Start Date*: 2012-05-31
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I1F-MC-RHAZ A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extensio...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) PL (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA